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Indomethac in and Retinopathy of Prematurity (ROP)
75
i n I n f a n t s
w i t h Patent Ductus Arter iosus (PDA)
S. Sun , A. Aranda , A. Caputo, V. Kamtorn
Flower et a I ( 1 ) , reported that a s p i r i n treated, oxygen-exposed
beagle p u p p i e s developed retinopathy of s i g n i f i c a n t l y greater
severity than the i r unmedicated, oxygen-exposed Ii t termates.
Direct ophthaImoscopic observations ind ica ted that whereas
susta ined oxygen b rea th ing produced r e t i n a l vasoconstriction
in unmedica ted p u p p i e s , r e t i n a l vessels of a s p i r i n treated
Iittermates became d i l a t e d or remained unchanged. The authors
conc luded that r e t i n a l vasoconstriction, i f v iewed as p h y s i o l o g i c
and protective, may be a b o l i s h e d by a pros tagland i n synthetase
i n h i b i t o r such as a s p i r i n , thereby a l l o w i n g a free f l o w of
hyperoxic blood into r e t i n a l t issue c a u s i n g oxygen damage.
Prompted by th i s observation, we reviewed our experience of the
past 8 years to determine whether the use of indomethac in , a
potent p r o s t a g l a n d i n synthetase i n h i b i t o r for closure of PDA,
made any d i f f e r e n c e in the inc idence and severity of ROP in
extremely low b i r t h weight i n f an t s .
M a t e r i a l & Method: We reviewed our experience in 75 PDA i n f a n t s
of less than 1001 gm at b i r t h who surv ived for more than 8 weeks
d u r i n g t h e past 8 years. A l l i n f a n t s be low th i s weight l i m i t
were considered to have PDA. Symptomatic PDA was d e f i n e d by
the presence of a systol ic m u r m u r , b o u n d i n g pu l se s , hyperactive
p reco rd ium, w i d e p u l s e pressure, increased p u l m o n a r y m a r k i n g s
and a l e f t a t r ia I to aortic root rat io of more than 1.3 determined
by echocardiogram. The c r i t e r i a for indomethac in treatment
i n c l u d e d one or more of the f o l l o w i n g : 1. congestive heart f a i l u r e ,
2. i n a b i l i t y to wean from the respirator, 3. i n a b i l i t y to p rov ide
s u f f i c i e n t ca lor ies for growth because of prolonged requi rement
o f f l u i d restr ict ion. Indomethac in was g iven v ia nasogastric
tube at a dose of 0.2 mg/kg/dose, subsequent doses were g iven
as i nd i ca t ed every 8 hours. No more than 6 doses were g iven
to a s i n g l e pat ient . The f o l l o w i n g i n f o r m a t i o n was extracted
from retrospective review of pat ient ' s records: 1. gestational
age, 2. b i r t h we igh t , 3. dura t ion of a r t e r i a l oxygen tension
(PaU2) or transcutaneous oxygen tension (TcPU2) more than 100
torr, 4. dura t ion of oxygen therapy, 5. dura t ion of a r t e r i a l
or c a p i l l a r y CÜ2 tension (PCÜ2) more than 50 torr and 6. dura t ion
of m e c h a n i c a l v e n t i l a t i o n .
I n d i r e c t ophthaImoscopy was performed by a p e d i a t r i c
o p h t h a l m o l o g i s t who had no knowledge of indomethac in treatment
at 4 to 6 weeks of age and a week before discharge. I n f a n t s
found to have r e t i n a l pathology were repeatedly examined d u r i n g
the i r hosp i t a l stay and in h i g h r i s k f o l l o w - u p c l i n i c a s an
outpatient.
Resul t s . Of the 75 patients, 29 had asymptomatic PDA, 20 had
symtomatic PDA but not treated w i t h indomethac in and 26 patients
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were symptomatic and had been treated w i t h indomethacin . (Tab le
I ) None of asymptomatic PDA in fan t s developed ROP. . (F i f t een percent
(3/15) of the symptomatic PDA in fan t s who had not been treated
w i t h indomethac in developed m i l d ROP. None progressed to
c i c a t r i c i a l ROP (cROP) . 'Th i r ty - f ive percent (9/26) of the
indomethacin treated PDA in f an t s developed ROP; more than h a l f
progressed t o c i c a t r i c i a l changes (Grade I I I t o V ) o f w h i c h 3
were b l i n d . The d i f f e r e n c e in the inc idence and severity of
ROP is s t a t i s t i c a l l y s i g n i f i c a n t among the three groups of i n f a n t s .
C o m p a r i n g the group of i n f a n t s who developed ROP w i t h those who
did not, there was no s i g n i f i c a n t d i f f e r ence in b i r t h we igh t ,
gestational age, length of mechan ica l v e n t i l a t i o n and dura t ion
of PCC>2 over 50 torr. In fan t s who developed ROP received
s i g n i f i c a n t l y longer 02 therapy and were exposed to longer hours
of hyperoxemia (P 2 <100 torr) .
C o n c l u s i o n : We b e l i e v e that
mu11 i f a c t o r i a I in nature and i t
rather than any s i n g l e factor
study shows that indomethac in treatment
the pathogenesis of ROP is
is the interactions among factors
a lone w h i c h are important. Our
may be one of those factors
c o n t r i b u t i n g to the development of ROP.
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ROP No ROP P*
No patient 9 27
Gestational age(wks) 27±1.4 27±1.0 NS
B i r t h w e i g h t ( g m ) 853±121 887±93 NS
Indomethacin R x ( « ) 6 (667.) 3 ( 1 1 . 1 « ) <0.005**
Ρθ£>100 torr (hrs) 11.6±6.6 6 .0±11 <0.02
02 therapy (days) 50±26 37±41 <0.05
PCU2 >50 torr (days) 144±218 63±113 NS
I M V (days) 17±8.5 21±25 NS
*Mann Whi tney Test
**Fisher Exact Test
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